Cargando…
The safety and acceptability of twice‐daily deferiprone for transfusional iron overload: A multicentre, open‐label, phase 2 study
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303221/ https://www.ncbi.nlm.nih.gov/pubmed/34931307 http://dx.doi.org/10.1111/bjh.17999 |
| _version_ | 1784751809104969728 |
|---|---|
| author | Badawy, Sherif M. Kattamis, Antonis Ezzat, Hatoon Deschamps, Benoît Sicard, Eric Fradette, Caroline Zhao, Feng Tricta, Fernando Chung Tsang, Yu Sheth, Sujit Piga, Antonio |
| author_facet | Badawy, Sherif M. Kattamis, Antonis Ezzat, Hatoon Deschamps, Benoît Sicard, Eric Fradette, Caroline Zhao, Feng Tricta, Fernando Chung Tsang, Yu Sheth, Sujit Piga, Antonio |
| author_sort | Badawy, Sherif M. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9303221 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-93032212022-07-22 The safety and acceptability of twice‐daily deferiprone for transfusional iron overload: A multicentre, open‐label, phase 2 study Badawy, Sherif M. Kattamis, Antonis Ezzat, Hatoon Deschamps, Benoît Sicard, Eric Fradette, Caroline Zhao, Feng Tricta, Fernando Chung Tsang, Yu Sheth, Sujit Piga, Antonio Br J Haematol Letters to the Editor‐online only John Wiley and Sons Inc. 2021-12-21 2022-04 /pmc/articles/PMC9303221/ /pubmed/34931307 http://dx.doi.org/10.1111/bjh.17999 Text en © 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
| spellingShingle | Letters to the Editor‐online only Badawy, Sherif M. Kattamis, Antonis Ezzat, Hatoon Deschamps, Benoît Sicard, Eric Fradette, Caroline Zhao, Feng Tricta, Fernando Chung Tsang, Yu Sheth, Sujit Piga, Antonio The safety and acceptability of twice‐daily deferiprone for transfusional iron overload: A multicentre, open‐label, phase 2 study |
| title | The safety and acceptability of twice‐daily deferiprone for transfusional iron overload: A multicentre, open‐label, phase 2 study |
| title_full | The safety and acceptability of twice‐daily deferiprone for transfusional iron overload: A multicentre, open‐label, phase 2 study |
| title_fullStr | The safety and acceptability of twice‐daily deferiprone for transfusional iron overload: A multicentre, open‐label, phase 2 study |
| title_full_unstemmed | The safety and acceptability of twice‐daily deferiprone for transfusional iron overload: A multicentre, open‐label, phase 2 study |
| title_short | The safety and acceptability of twice‐daily deferiprone for transfusional iron overload: A multicentre, open‐label, phase 2 study |
| title_sort | safety and acceptability of twice‐daily deferiprone for transfusional iron overload: a multicentre, open‐label, phase 2 study |
| topic | Letters to the Editor‐online only |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303221/ https://www.ncbi.nlm.nih.gov/pubmed/34931307 http://dx.doi.org/10.1111/bjh.17999 |
| work_keys_str_mv | AT badawysherifm thesafetyandacceptabilityoftwicedailydeferipronefortransfusionalironoverloadamulticentreopenlabelphase2study AT kattamisantonis thesafetyandacceptabilityoftwicedailydeferipronefortransfusionalironoverloadamulticentreopenlabelphase2study AT ezzathatoon thesafetyandacceptabilityoftwicedailydeferipronefortransfusionalironoverloadamulticentreopenlabelphase2study AT deschampsbenoit thesafetyandacceptabilityoftwicedailydeferipronefortransfusionalironoverloadamulticentreopenlabelphase2study AT sicarderic thesafetyandacceptabilityoftwicedailydeferipronefortransfusionalironoverloadamulticentreopenlabelphase2study AT fradettecaroline thesafetyandacceptabilityoftwicedailydeferipronefortransfusionalironoverloadamulticentreopenlabelphase2study AT zhaofeng thesafetyandacceptabilityoftwicedailydeferipronefortransfusionalironoverloadamulticentreopenlabelphase2study AT trictafernando thesafetyandacceptabilityoftwicedailydeferipronefortransfusionalironoverloadamulticentreopenlabelphase2study AT chungtsangyu thesafetyandacceptabilityoftwicedailydeferipronefortransfusionalironoverloadamulticentreopenlabelphase2study AT shethsujit thesafetyandacceptabilityoftwicedailydeferipronefortransfusionalironoverloadamulticentreopenlabelphase2study AT pigaantonio thesafetyandacceptabilityoftwicedailydeferipronefortransfusionalironoverloadamulticentreopenlabelphase2study AT badawysherifm safetyandacceptabilityoftwicedailydeferipronefortransfusionalironoverloadamulticentreopenlabelphase2study AT kattamisantonis safetyandacceptabilityoftwicedailydeferipronefortransfusionalironoverloadamulticentreopenlabelphase2study AT ezzathatoon safetyandacceptabilityoftwicedailydeferipronefortransfusionalironoverloadamulticentreopenlabelphase2study AT deschampsbenoit safetyandacceptabilityoftwicedailydeferipronefortransfusionalironoverloadamulticentreopenlabelphase2study AT sicarderic safetyandacceptabilityoftwicedailydeferipronefortransfusionalironoverloadamulticentreopenlabelphase2study AT fradettecaroline safetyandacceptabilityoftwicedailydeferipronefortransfusionalironoverloadamulticentreopenlabelphase2study AT zhaofeng safetyandacceptabilityoftwicedailydeferipronefortransfusionalironoverloadamulticentreopenlabelphase2study AT trictafernando safetyandacceptabilityoftwicedailydeferipronefortransfusionalironoverloadamulticentreopenlabelphase2study AT chungtsangyu safetyandacceptabilityoftwicedailydeferipronefortransfusionalironoverloadamulticentreopenlabelphase2study AT shethsujit safetyandacceptabilityoftwicedailydeferipronefortransfusionalironoverloadamulticentreopenlabelphase2study AT pigaantonio safetyandacceptabilityoftwicedailydeferipronefortransfusionalironoverloadamulticentreopenlabelphase2study |